Business Context and Reporting Period
This Form 10-Q covers LecTec Corporation (Note: Metadata listed "Axogen, Inc." but the filing text identifies the registrant as LecTec Corporation) for the quarterly and nine-month periods ended March 31, 2001. The company operates in a single segment focused on advanced skin interface technologies, including therapeutic consumer products, conductive products, and medical tape products. The company is currently executing a strategic shift, exiting the medical tape business and selling assets related to its conductive products division.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2001 | Nine Months Ended Mar 31, 2001 |
|---|---|---|
| Net Sales | $4,171,778 | $12,417,156 |
| Gross Profit | $1,436,641 (34.4% margin) | $4,429,445 (35.7% margin) |
| Net Loss | $(543,781) | $(1,833,679) |
| Loss Per Share (Basic/Diluted) | $(0.14) | $(0.47) |
| Cash and Cash Equivalents | $48,384 (Ending Balance) | Net decrease of $51,787 |
| Working Capital | $1,081,274 | N/A |
| Current Ratio | 1.3 | N/A |
| Debt Obligations | Line of Credit: $435,667; Mortgage: $834,639 (Long-term) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6.0% for the quarter and 21.2% for the nine-month period compared to the prior year. This growth was driven by a 59.1% quarterly increase in therapeutic consumer products (specifically the Triaminic vapor product), which offset declines in conductive products (-2.5%) and medical tape products (-105.3%).
- Profitability: While gross profit increased 26.1% year-over-year for the nine months, the company reported a net loss for both periods. The quarterly loss narrowed from $643,328 to $543,781, aided by a one-time gain on asset sales.
- Asset Dispositions: The company sold medical tape manufacturing equipment in March 2001 for net proceeds of $630,000, realizing a gain of $103,624. This finalized the exit from the medical tape business.
- Debt Structure: Interest expense rose significantly (from $6,732 to $44,932 for the quarter) due to increased borrowings under a line of credit and a new $820,000 mortgage secured by real property.
Guidance, Outlook, and Risks
- Asset Sale Transaction: The company entered an agreement to sell its diagnostic electrode and conductive adhesive hydrogel business assets. Closing occurred on April 30, 2001, with an expected gain of approximately $4,400,000 to be recognized in the fourth quarter of fiscal 2001.
- Future Operations: Following the asset sale, the company will continue to manufacture conductive products for the buyer under a nine-month supply agreement. Sales are expected to decrease in the remainder of fiscal 2001.
- Liquidity: Management believes existing cash, the $2.8 million line of credit, the mortgage loan, and proceeds from the asset sale will fund operations through fiscal 2002. However, future funding may require additional equity or debt investments.
- Risks: Key risks include dependence on major customers (e.g., Novartis, Johnson & Johnson), competitive pricing pressures, regulatory approvals, and the ability to control operating expenses. The company has a valuation allowance for deferred taxes, offsetting income tax provisions.
Investor Verification Checklist
- Asset Sale Closing: Verify the final closing details and the exact gain recognition of the conductive business asset sale (expected ~$4.4M) in the Q4 2001 filing.
- Supply Agreement Terms: Review the specific terms of the nine-month Manufacturing and Supply Agreement with the buyer of the conductive assets to understand future revenue streams.
- Debt Covenants: Confirm continued compliance with restrictive covenants on the line of credit, specifically regarding net worth and cumulative loss limits.
- Customer Concentration: Assess the impact of the new Triaminic and acne product sales on revenue stability, given the heavy reliance on Novartis and Johnson & Johnson.
- Cash Burn Rate: Monitor the net cash used in operating activities ($678,754 for nine months) against available liquidity to ensure sufficiency through fiscal 2002.